Spero Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 46
- Market Cap
- $74.5M
- Introduction
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
Phase 2
Terminated
- Conditions
- Mycobacterium Avium ComplexNon-tuberculous Mycobacterium Pulmonary Disease
- Interventions
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT04553406
- Locations
- 🇺🇸
Medical Facility, Pittsburgh, Pennsylvania, United States
Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - TestDrug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT04421885
- Locations
- 🇺🇸
Medical Facility, Tempe, Arizona, United States
Effect of Tebipenem on Normal Human Intestinal Microbiota
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: amoxicillin-clavulanate
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04376554
- Locations
- 🇸🇪
Karolinska University Hospital, Huddinge, Stockholm, Sweden
Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)Drug: 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT04368585
- Locations
- 🇺🇸
Medical Facility, Phoenix, Arizona, United States
A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects
Phase 1
Completed
- Conditions
- TQT Study
- Interventions
- Drug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + PlaceboDrug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)Other: Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT04238195
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function
Phase 1
Completed
- Conditions
- Renal Impairment
- Interventions
- Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT04178577
- Locations
- 🇺🇸
Medical Facility, Orlando, Florida, United States
A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo for MADDrug: SPR720 for SADDrug: SPR720 for MADDrug: Placebo for SAD
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 96
- Registration Number
- NCT03796910
- Locations
- 🇬🇧
Simbec Research, Ltd., Merthyr Tydfil,, Mid Glamorgan, United Kingdom
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy Volunteers
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 94
- Registration Number
- NCT03792308
- Locations
- 🇦🇺
Scientia Clinical Research Ltd., Randwick, New South Wales, Australia
Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Phase 3
Completed
- Conditions
- Complicated Urinary Tract InfectionAcute Pyelonephritis
- Interventions
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 1372
- Registration Number
- NCT03788967
- Locations
- 🇷🇺
Medical facility, Saint Petersburg, Russian Federation
🇺🇦Medical Facility, Zhytomyr, Ukraine
Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 124
- Registration Number
- NCT03395249
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, Randwick, New South Wales, Australia
© Copyright 2025. All Rights Reserved by MedPath